ClinConnect ClinConnect Logo
Search / Trial NCT06600815

Analgesic Efficacy of Preemptive Stepwise Infiltration Anesthesia for Perioperative Analgesia After TKA

Launched by FIRST AFFILIATED HOSPITAL OF FUJIAN MEDICAL UNIVERSITY · Sep 17, 2024

Trial Information

Current as of November 12, 2025

Recruiting

Keywords

Total Knee Arthroplasty Pain Management Anaesthesia In Orthopaedics

ClinConnect Summary

This clinical trial is investigating two different methods of pain management for patients undergoing total knee arthroplasty (TKA), a surgery to replace a damaged knee joint. The study aims to see which method—preemptive stepwise infiltration anesthesia (PSIA), given before the surgery, or postoperative local infiltration analgesia (PLIA), given after the surgery—provides better pain relief and reduces inflammation. Participants will be monitored at various times before and after the surgery to compare their experiences of pain and recovery.

To be eligible for the study, participants must be at least 18 years old and diagnosed with knee osteoarthritis that requires TKA. They should be in good enough health to undergo surgery, with specific criteria ensuring they don’t have previous knee surgeries, certain medical conditions, or allergies that could complicate the trial. Those who take high doses of pain medication regularly or who are pregnant or breastfeeding will also be excluded. If you decide to participate, you’ll be part of a team that seeks to improve pain management for future patients undergoing this common procedure.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients must meet all of the following criteria to be eligible for inclusion:
  • 1. Clinical diagnosis of primary unilateral knee osteoarthritis (KOA), confirmed by imaging as KOA (Kellgren-Lawrence score ≥2). The patient was scheduled for initial unilateral total knee arthroplasty (TKA) at our hospital.
  • 2. Preoperative American Society of Anaesthesiologists (ASA) score ranging from 1 to 3. Surgeons deemed the patient eligible for TKA based on the evaluation criteria.
  • 3. Participants aged 18 years or older, both male and female.
  • 4. Ability to provide informed consent and sign a written informed consent form.
  • 5. The ability to comprehend the research requirements and willingness to cooperate with the study instructions.
  • Exclusion Criteria:
  • Patients will be excluded if they meet any of the following criteria:
  • 1. Previous knee surgery on the operative knee or a history of infection in the operative knee.
  • 2. Patients diagnosed with conditions other than osteoarthritis (including rheumatoid arthritis, traumatic arthritis, septic arthritis and haemophilic arthritis).
  • 3. Severe osteoarthritis (including flexion contracture \>30° or varus/valgus deformity \>30° and the use of unconventional arthroplasty components due to complex joint pathology \[e.g., restrictive prostheses\]).
  • 4. Allergy to the investigational drug.
  • 5. The presence of neuromuscular dysfunction on the operative side.
  • 6. Dependence on anaesthesia drugs (defined as the use of opioid or local anaesthetic drugs exceeding 100 mg of morphine equivalents per week to control preoperative pain for more than 3 months).
  • 7. Poor overall health conditions, including but not limited to a glycated haemoglobin level exceeding 12%; blood pressure exceeding 170/110 mmHg; myocardial infarction, stroke, transient ischaemic attack, acute congestive heart failure, or any acute coronary events within the past 6 months; severe hepatic or renal dysfunction; and pregnancy or lactation.
  • 8. Concurrent participation in clinical trials other than this trial.

About First Affiliated Hospital Of Fujian Medical University

The First Affiliated Hospital of Fujian Medical University is a leading medical institution dedicated to advancing healthcare through innovative clinical research and education. As a premier sponsor of clinical trials, the hospital is committed to improving patient outcomes and contributing to medical knowledge across various specialties. With a robust infrastructure and a multidisciplinary team of experienced researchers and healthcare professionals, the hospital ensures the ethical conduct and scientific rigor of its trials, fostering collaboration with global research communities. Its mission is to enhance the quality of care through evidence-based practices and to support the development of novel therapies that address unmet medical needs.

Locations

Fuzhou, Fujian, China

Patients applied

0 patients applied

Trial Officials

Wenming Zhang, MD

Study Director

First Affiliated Hospital of Fujian Medical University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported